Anti-inflammatory properties of nimesulide and clarithromycin: a comparative study during the therapy of bronchial sepsis involving P.aeruginosa Source: Eur Respir J 2002; 20: Suppl. 38, 373s Year: 2002
Immunoregulatory effect of a 14-membered ring macrolide antibiotic in cystic fibrosis patients Source: Eur Respir J 2001; 18: Suppl. 33, 126s Year: 2001
Long-term macrolide therapy in chronic inflammatory airway diseases Source: Eur Respir J 2009; 33: 171-181 Year: 2009
Pirfenidone, proton pump inhibitor, N acetyl cysteine (PINPOINT) therapy for IPF: Tolerance and safety profile among Indian patients Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012
Treatment outcome of combination antibiotic therapy including clarithromycin for Mycobacterium avium complex pulmonary disease Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis Year: 2010
Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP) Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008
Treatment of lymphangioleiomyomatosis with anastrozole; a potent and selective non-steroidal aromatase inhibitor Source: Eur Respir J 2007; 30: Suppl. 51, 67s Year: 2007
Anti-inflammatory therapies in bronchiectasis Source: Eur Respir Mon 2011; 52: 223-238 Year: 2011
Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Combination therapy (beta-lactam+macrolide) vs fluoroquinolone monotherapy for the treatment of CAP Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012
The inhibitory effect of ciprofloxacin on bacterial adhesiveness is enhanced by the SH-metabolite I of erdosteine (mucolytic drug) Source: Eur Respir J 2001; 18: Suppl. 33, 543s Year: 2001
Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002
An anti-inflammatory effect of azithromycin in cystic fibrosis Source: Annual Congress 2010 - New aspects of cystic fibrosis Year: 2010
A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006
Smoking has no effect on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
The bronchodilatory and anti-inflammatory effect of MT-810, a novel selective phosphodiesterase-4 (PDE4) inhibitor Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006